| 초록 |
Our recent studies demonstrated that the tumor-targeting efficiency of PEGylated nanocarriers can be improved substantially, by replacing a significant portion of PEG surface groups with small functionalities. These small surface groups, which were embedded in the interior of partially PEGylated nanocarriers, varied in physicochemical properties, and impacted differently on tumor-targeting efficiencies in vitro and in vivo. One of the most likely causes for such discrepancy is the potential of a nanocarrier to form protein corona with serum proteins, such as albumin, when administered intravascularly. Here we conducted in vitro and in vivo studies using our compounds and tumor cells, which either can or cannot release SPARC that is known to facilitate the cellular uptake of albumin-associated nanocarriers. We envision that our systematic investigation may provide a useful guideline on redesigning the nanocarrier PEG surface for tumor targeting, suitable for clinical translation. |
